|
WO2020102394A1
|
|
Respirable polynucleotide powder formulations for inhalation
|
|
JP2019108379A
|
|
Rapid relief of motor fluctuations in parkinson's disease
|
|
AU2018392461A1
|
|
Surfactant formulations for inhalation
|
|
WO2019126283A1
|
|
Surfactant formulations for inhalation
|
|
WO2017223502A1
|
|
Surfactant formulations for inhalation
|
|
MX2017016423A
|
|
Triptan powders for pulmonary delivery.
|
|
AU2016257729A1
|
|
Zolmitriptan powders for pulmonary delivery
|
|
AU2015342919A1
|
|
Rapamycin powders for pulmonary delivery
|
|
CA2946165A1
|
|
Rapid relief of motor fluctuations in parkinson's disease
|
|
NZ747378A
|
|
Ultra low density pulmonary powders
|
|
BR112015010601A2
|
|
pulmonary powders of ultra low density.
|
|
NZ747373A
|
|
Reducing inter-patient variability of levodopa plasma concentrations
|
|
CA2888994A1
|
|
Levodopa formulations for rapid relief of parkinson's disease
|
|
US2014150787A1
|
|
Devices and methods for puncturing a capsule to release a powdered medicament therefrom
|
|
US8545878B1
|
|
Capsules containing high doses of levodopa for pulmonary use
|
|
EP1635762A2
|
|
Low dose pharmaceutical powders for inhalation
|
|
EP3308772A1
|
|
Inhalable epinephrine
|
|
EP1531798A2
|
|
Pulmonary delivery for levodopa
|
